ClinicalTrials.Veeva

Menu

Addition of Pyridoxine to Prednisolone in Infantile Spasms

L

Lady Hardinge Medical College

Status and phase

Completed
Phase 3

Conditions

Infantile Spasms

Treatments

Drug: Pyridoxine plus prednisolone
Drug: Prednisolone

Study type

Interventional

Funder types

Other

Identifiers

NCT01828437
PYRIPREDIS

Details and patient eligibility

About

Infantile spasms constitute a unique age specific epilepsy syndrome of infancy, characterized by epileptic spasms often accompanied by neurodevelopmental regression and an EEG finding of hypsarrhythmia. When all 3 components are present, the eponym "West syndrome" is commonly used. West syndrome is a catastrophic epileptic encephalopathy. It does not respond well to standard anti-epileptic drugs. Hormonal therapy is the mainstay in the treatment of infantile spasms. This includes adreno-cortico trophic hormone (ACTH) and oral steroids. Variable dose of prednisolone used in the treatment. Oral prednisolone used in usual dose (2mg/kg) has been shown to be less effective as compared to ACTH. High dose prednisolone (4mg/kg) has been used in the treatment of infantile spasms, which has been shown to be as effective as ACTH. Pyridoxine has been used as first line treatment in Japan, however there is paucity of data on the efficacy of combination of pyridoxine with hormonal therapy. There are no studies comparing add on pyridoxine with high prednisolone versus high dose prednisolone alone in the treatment of infantile spasms. Therefore the study has been planned to see whether the addition of pyridoxine with high dose prednisolone in the treatment of infantile spasms improves the efficacy in terms of spasm cessation.

Enrollment

62 patients

Sex

All

Ages

3 to 36 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age in 3months-3years.

  2. Presence of epileptic spasms (1 or more clusters per day) with EEG evidence of hypsarrythmia or its variants.

Exclusion criteria

  1. Children with active systemic illness

  2. Children with evidence of active tuberculosis

  3. Severe Acute Malnutrition (standard deviation scores below median weight for height)

  4. Children with recurrent illness/chronic systemic illness

  5. Prior treatment of pyridoxine, steroid, or ACTH.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

62 participants in 2 patient groups

Pyridoxine plus prednisolone
Experimental group
Description:
allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
Treatment:
Drug: Pyridoxine plus prednisolone
Prednisolone
Active Comparator group
Description:
allocated patients receive prednisolone alone
Treatment:
Drug: Prednisolone

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems